Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, today announced ...
TipRanks on MSN

BioVersys Initiates Phase 1 Trial of BV100 in China to Combat Drug-Resistant Infections

BioVersys AG ( ($CH:BIOV) ) just unveiled an announcement. BioVersys AG has initiated the Phase 1 clinical trial of BV100 in China, marking a ...
Nasdaq

Cerevance Reports Positive Phase 1 Clinical Trial Results for KCNK13 Inhibitor and Upcoming Presentations at AAIC 2025

Cerevance announced Phase 1 trial results for CVN293 and NETSseq insights at AAIC 2025, highlighting advancements in neurodegenerative disease treatments. Cerevance, a biopharmaceutical company ...

Normunity announces first patient dosed in Phase 1 clinical study of NRM-823, a T Cell Engager against a novel tumor-specific target, in patients with solid tumors

Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastatic refractory solid tumors NRM-823 is a T cell ...

Vir Biotechnology concludes Eclipse 1 Phase III trial enrolment for CHD

Vir Biotechnology has concluded subject enrolment for the Phase III Eclipse 1 trial assessing the efficacy and safety of ...
Eagle-Tribune

ICON’s Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 ...
Morningstar

Vascarta Announces Completion of Phase 1 Clinical Trial of VAS-101 for the Treatment of Osteoarthritis

SUMMIT, N.J., Sept. 29, 2025 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful ...
The Manila Times

CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing

CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) ('CERo” or the 'Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces the ...
Ophthalmology Times

4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial

4D Molecular Therapeutics (4DMT) released positive interim 1.5- to 3.5-year data from the phase 1/2 PRISM clinical trial ...

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that Phase 1/2 interim results from its U.S. NXC-201 ...

Kidney drug trial raises hopes for new type 1 diabetes treatment

The results of a late-stage drug trial released Thursday are raising hopes that type 1 diabetes patients with chronic kidney ...
The Manila Times

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit ...

D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all ...